House Speaker Paul Ryan (R-WI) yesterday discussed a potential compromise on the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974/H.R. 2212), as part of congressional action to address high drug prices. “We’re working between the Commerce Committee and the Judiciary Committee on a compromise on what we call CREATES, which is getting the generics online faster after patents have expired, so I think there are things we can do in that area,” Ryan said, according to published reports, during an event hosted by a Washington, D.C. law firm. Among other provisions, the legislation would allow a generic drug manufacturer facing a sample-sharing delay tactic to bring an action in federal court for injunctive relief and allow a judge to award damages to deter future delaying conduct. Earlier this year, AHA and more than 40 organizations urged Congress to pass the legislation calling it “a narrowly targeted, bipartisan, pro-competition and market-based solution to these abuses that cost patients, job-creators and taxpayers billions of dollars each year.”

Related News Articles

Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
Congress should pass legislation that would protect patients from surprise medical bills; preserve the ability of providers and insurers to negotiate private…
Headline
The House Energy and Commerce Subcommittee on Health today passed the No Surprises Act (H.R. 3630), bipartisan legislation that would prohibit balance billing…
Headline
The Trump administration today withdrew a proposed rule that would eliminate the rebate safe harbor for pharmacy benefit managers under the federal anti-…
Headline
The House Energy and Commerce Subcommittee on Health tomorrow is scheduled to mark up 10 health-related bills, including the No Surprises Act — bipartisan…
Headline
A federal judge yesterday struck down a Centers for Medicare…